Patent classifications
C07D487/00
METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF
A compound represented by Formula [3] or a salt thereof and a method of making the
##STR00001## in the formula, L.sup.3 represents a group represented by Formula [2c]
##STR00002## wherein R.sup.3c, R.sup.4c, R.sup.5c and R.sup.6c are the same as or different from each other and represent a hydrogen atom or a C.sub.1-6 alkyl group; p.sup.3 represents an integer of 1 to 3; q.sup.3 represents an integer of 0 to 3; and r.sup.3 represents an integer of 1 to 6; A.sup.1 represents any one of the groups represented by Formulae [4] to [9],
##STR00003## wherein * represents a binding position; and R.sup.7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.
METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF
A compound represented by Formula [3] or a salt thereof and a method of making the
##STR00001## in the formula, L.sup.3 represents a group represented by Formula [2c]
##STR00002## wherein R.sup.3c, R.sup.4c, R.sup.5c and R.sup.6c are the same as or different from each other and represent a hydrogen atom or a C.sub.1-6 alkyl group; p.sup.3 represents an integer of 1 to 3; q.sup.3 represents an integer of 0 to 3; and r.sup.3 represents an integer of 1 to 6; A.sup.1 represents any one of the groups represented by Formulae [4] to [9],
##STR00003## wherein * represents a binding position; and R.sup.7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.
USE OF SRC FAMILY KINASE INHIBITOR IN RIBOSOMAL DISORDER
The present disclosure provides methods and compositions for the use of a Src family kinase (SFK) inhibitor for the treatment of anemia associated with ribosomal disorders, such as diamond blackfan anemia.
SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF
The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.
##STR00001##
CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.
CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.
Therapeutic compounds
The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): ##STR00001## ##STR00002##
which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents
The present invention provides a compound of Formula II, and salts thereof, and a pharmaceutical composition comprising a compound of Formula II:
##STR00001##
wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, and wherein R.sub.3 is hydrogen, an alkyl group having from one to ten carbon atoms, or a halogen. Preferably the compound of Formula II includes wherein R.sub.3 is a halogen, and most preferably wherein the halogen is chlorine. Methods of treating a patient with cancer with these compounds are also provided.
Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
The present invention relates to 4-phenetylamino-7H-pyrrolo[2,3-d]pyrimidine derivatives of the and solvates, hydrates and pharmaceutically acceptable salts thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the prevention and/or treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia. Said 4-phenetylamino-7H-pyrrolo[2,3-d]pyrimidine compounds have been identified as new drug candidates for the prevention and/or treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia.
Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
The present invention relates to 4-phenetylamino-7H-pyrrolo[2,3-d]pyrimidine derivatives of the and solvates, hydrates and pharmaceutically acceptable salts thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the prevention and/or treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia. Said 4-phenetylamino-7H-pyrrolo[2,3-d]pyrimidine compounds have been identified as new drug candidates for the prevention and/or treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia.